Every 8-K that BioNexus Gene Lab Corp (BGLC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BGLC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BGLC filings page.
BioNexus Gene Lab Corp. outlines continued progress toward commercializing the VitaGuard™ molecular residual disease (MRD) liquid‑biopsy platform in Southeast Asia after a working visit to Tongshu Gene facilities in Shanghai and Changzhou, where VitaGuard is in paid commercial use at numerous hospitals in China.
VitaGuard is a tumor‑naive, fixed‑panel next‑generation sequencing test for detecting circulating tumor DNA associated with MRD in solid tumors, designed to simplify repeat blood‑based monitoring. BioNexus holds exclusive rights for VitaGuard‑based products and services in ten Southeast Asian markets and owns approximately 15% of Fidelion Diagnostics, which holds VitaGuard intellectual‑property rights outside China.
Management has previously indicated an expected VitaGuard cost per test of under US$300, and the ten licensed markets together have a population of more than 680 million people. Following the visit, BioNexus and Fidelion are working on documentation transfer, local verification and validation, and regulatory and commercial preparations in Malaysia and Singapore, targeting initial deployment in selected regional medical hubs during 2026, subject to completion of this work and applicable approvals.
BioNexus Gene Lab Corp. highlighted its role in the 2026 China–Malaysia Economic Cooperation Outlook Forum, where CEO Sam Tan advocated moving Malaysia–China biotechnology ties beyond simple trade and toward co-development, clinical validation, and regional commercialization.
The company described a Malaysia-based ASEAN “execution hub” model using examples such as Fidelion Diagnostics and the VitaGuard™ MRD platform, linking China-origin biotechnology with international commercialization vehicles, clinical validation, and regulatory discipline. BioNexus emphasized precision diagnostics, liquid biopsy, minimal residual disease monitoring, and AI-assisted healthcare, and outlined collaboration pillars including accelerated validation of China-origin precision oncology tools, infrastructure for scalable labs, and AI-integrated healthcare that respects regional data sovereignty and privacy.
BioNexus Gene Lab Corp. appointed Dr. Muthu Meyyappan as Chief Commercial Officer of its affiliate Fidelion Diagnostics in connection with the Fidelion transaction. Fidelion is the international commercialization and intellectual property vehicle for the VitaGuard™ minimal residual disease liquid biopsy platform developed by Tongshu Gene.
Dr. Meyyappan will lead Fidelion’s global commercial strategy and partnerships to drive adoption of advanced oncology diagnostic technologies. BioNexus holds exclusive rights to commercialize VitaGuard™ across Southeast Asia through a licensing arrangement with Fidelion, supporting its strategy to expand access to precision oncology diagnostics in the region.
BioNexus Gene Lab Corp. announced it has completed a governance restructuring of its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd., and appointed Matthew L. Barsing as Chairman alongside BioNexus CFO Angeline Chong as director on Chemrex’s streamlined two-member board.
The company has centralized financial supervision and strengthened capital expenditure review and reporting protocols at Chemrex to align more closely with parent-level governance standards. A previously approved staged capital allocation framework supports potential expansion initiatives, while Chemrex’s strategic options, including biotechnology and advanced manufacturing directions, remain under evaluation with no definitive commitments yet.
BioNexus Gene Lab Corp. reported that it has formally begun the 2026 regional deployment phase of its VitaGuard™ Minimal Residual Disease (MRD) platform. This marks a shift from development-stage technology to operational deployment focused on Southeast Asia.
The company plans to integrate VitaGuard™ into routine oncology workflows at select regional medical hubs during 2026. It expects this phase to support broader commercialization, expand access to longitudinal cancer monitoring, and generate high-frequency molecular data for future AI-assisted oncology initiatives.
The update also notes that by the end of 2025 the company advanced global patent filings, set up its international commercialization structure, pursued recruitment, and planned Southeast Asia market entry with a regional diagnostics partner. Fidelion Diagnostics Pte. Ltd. will serve as the international intellectual property and commercialization vehicle outside Greater China.
BioNexus Gene Lab Corp. entered into an Equity Distribution Agreement with Maxim Group LLC to establish an at-the-market program under which the Company may offer and sell up to $20,000,000 of common stock, from time to time, through the agent.
Sales, if any, may be made on The Nasdaq Capital Market or otherwise at prevailing, related, or negotiated prices. The Company is not obligated to sell shares, and the agent is not required to purchase shares. No sales will occur unless the Company’s shelf Registration Statement on Form S-3 (File No. 333-291379) is declared effective and an applicable prospectus supplement is filed.
The agreement includes customary representations, covenants, indemnification, and termination rights. The Company also announced the ATM program via a press release furnished as an exhibit.
BioNexus Gene Lab Corp. (BGLC) entered a definitive share subscription and shareholders’ agreement with Fidelion Diagnostics to form a strategic alliance around the VitaGuard MRD platform. Upon completion, BGLC will subscribe for new Fidelion shares to hold at least 15.0% of Fidelion’s enlarged capital, and will issue restricted shares representing 19.9% of BGLC’s outstanding common stock (pre-issuance) to Fidelion as consideration.
Closing is subject to specified conditions precedent, including an exclusive Southeast Asia IP license between BGLC and Fidelion and customary consents. Governance terms allow BGLC to appoint two directors to Fidelion’s board (one Singapore resident), with reserved matters requiring enhanced approvals. Transfer restrictions, pre-emptive and over‑subscription rights, and SIAC arbitration are included.
Related‑person disclosure: as of November 11, 2025, BGLC’s CEO Su‑Leng Tan Lee beneficially owns approximately 4.1% of Fidelion and is expected to serve as Fidelion’s initial CEO; independent and disinterested directors approved the transactions, and he abstained. The BGLC share issuance will be conducted offshore under Regulation S.
BioNexus Gene Lab Corp. (BGLC) furnished a press release under Regulation FD announcing a non-binding Strategic Partnership Term Sheet with BirchBioMed Inc. The proposed collaboration contemplates BGLC leading Birch’s current financing round via a strategic equity investment and jointly commercializing Birch’s FS2 (kynurenic acid) topical platform in Southeast Asia.
The Term Sheet is described as a framework for continued discussions, and the company notes there is no assurance a definitive agreement will be executed or that the contemplated transactions will be completed.
BioNexus Gene Lab Corp. (Nasdaq: BGLC) filed an 8-K to disclose a Regulation FD communication. On 30 July 2025 the company signed a non-binding term sheet with Singapore-based Fidelion Diagnostics Pte Ltd. The parties are negotiating a cross-equity strategic alliance and have granted BGLC exclusive commercialization rights in Southeast Asia to Fidelion’s VitaGuard™ minimal-residual-disease (MRD) testing platform, a precision-oncology technology aimed at detecting trace cancer cells post-treatment.
The agreement is still preliminary; no financial terms, timelines or definitive contracts were announced. The company framed the deal as a potential “DeepSeek Moment” for oncology diagnostics in the region. No guidance, revenue impact or financing details accompanied the disclosure, and the item is being furnished, not filed, so it carries no immediate accounting effect.